• Age ≥ 18 years of age

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

• Histologically confirmed carcinoma of the prostate

• Progressing on continuous androgen ablative therapy (either surgical castration or LHRH agonist)

• Documented castrate level of blood testosterone (\< 50 ng/dL)

• Patients must have progressed on prior treatment with at least one Androgen Receptor Signaling Inhibitors (ARSI) and at least one chemotherapy (by prostate specific antigen \[PSA\] criteria or radiographically)

• Have biopsiable disease (a fresh biopsy is not required at baseline if adequate archival tissue is available)

• Absolute neutrophil count: ≥1,200/µL

• Platelets: ≥ 100,000/µL

• Total bilirubin: ≤ 1.2 x institutional upper limit of normal (ULN)

• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/ Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]): ≤ 3 × institutional ULN

• Creatinine clearance (CrCl) \> 50 mL/min (Cockcroft-Gault equation)

• Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present

• Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

• Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure